To investigate the clinical efficacy of medical infrared cough gel combined with recombinant human interferon α2b aerosol inhalation in the treatment of chronic bronchitis to alleviate patients' suffering and improve their quality of life.

This was a retrospective study of the clinical data of 120 patients with chronic bronchitis admitted to Shenzhen Renkang Hospital from January 2022 to January 2024. The patients were divided into the experimental group and the control group according to different treatment methods, with 60 patients in each group. The control group was treated with recombinant human interferon α2b aerosol inhalation, and the observation group was treated with medical infrared cough gel in addition to the control group, and both groups were treated for 5～7 days. The clinical efficacy, improvement time of clinical symptoms, hospitalization time, and pulmonary function indicators were observed and compared.

The total effective rate of the observation group after treatment was higher than that of the control group, with a statistically significant difference (P<0.05). The time for the disappearance of clinical symptoms and the hospitalization time in the observation group were both shorter than those in the control group, with statistically significant differences (P<0.05). After treatment, the levels of FEV₁/FVC, FEV₁%pred, MVV, tidal volume, peak time ratio, and peak volume ratio in the observation group were all higher than those in the control group, and the level of serum creatinine in the observation group was lower than that in the control group, with statistically significant differences (P<0.05). After treatment, the levels of interleukin-18, interleukin-17, and C-reactive protein in the observation group were lower than those in the control group, with statistically significant differences (P<0.05).

The combined use of medical infrared cough-relieving gel and recombinant human interferon α₂b aerosol inhalation therapy for chronic bronchitis has significant effects, can effectively improve clinical symptoms, shorten recovery time, and improve pulmonary function indicators.